Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States Superior Court of the State of California, County of Alameda, on behalf of investors who purchased ZELTIQ Aesthetics, Inc. (“ZELTIQ” or the “Company”) (Nasdaq: ZLTQ) stock pursuant and/or traceable to the Company’s Initial Public Offering (“IPO”) commenced on or about October 19, 2011. The Complaint alleges that the defendants failed to disclose material adverse facts about the Company’s business and prospects, including disruptions in sales and a resulting deceleration in the Company’s growth rate.
For more information, click here:
. There is no cost or obligation to you.
On March 6, 2012, ZELTIQ announced fourth quarter 2011 sales and profits substantially below analysts’ estimates. The Company also estimated 2012 sales of approximately $90 million to $94 million, significantly below analysts’ estimates of $114 million. On this news, ZELTIQ common stock fell nearly 34%, to close that day at $7.36, on unusually heavy trading volume.
If you suffered a loss in ZELTIQ you have until May 17, 2012
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at
or by telephone at (877) 363-5972, or visit
Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.